证券代码：002038 证券简称：双鹭药业 公告编号：2026-002 北京双鹭药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、股票交易异常的基本情况 （二）公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大影响的未 公开重大信息。 （三）公司近期经营情况正常，内外部经营环境未发生重大变化。 （四）公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重大事项， 或处于筹划阶段的重大事项。 （五）公司于 2026 年 1 月 31 日披露了《2025 年度业绩预告》："报告期内，公司非经 常性损益合计减少净利润约 2 亿元，其中：确认的理财投资损失与交易性金融资产等产生的 公允价值变动收益是主要影响因素。本报告期确认损失金额中包括公司投资理财损失，该投 资损失公司目前正在以各种方式挽回。为维护公司利益，保护中、小股东利益不受损害，徐 明波董事长自愿承诺该投资理财无法挽回的差额部分最终确认后由其补足。徐明波董事长在 一个月内先将 5000 万资金上缴公司。公司目前货币资金充裕，生产经营正常，预计该事项 ...

Market Overview - The A-share market showed a strong rebound today, with the Shanghai Composite Index rising by 0.24%, while Japanese and Korean markets fell by nearly 3% each, indicating a competitive advantage for China [1] - The total market turnover reached 19,277.83 billion yuan, an increase of 637.87 billion yuan compared to the previous day, with over 2,800 stocks rising [21] Sector Performance - The aluminum sector led the gains, with companies like Tianshan Aluminum and Chang Aluminum hitting the daily limit. This surge is attributed to attacks on two Middle Eastern aluminum producers, which disrupted global aluminum supply chains [21][31] - The pharmaceutical sector continued to perform well, with stocks like Meinuo Pharma achieving five consecutive limits. The first quarter saw China's innovative drug licensing transactions exceed $60 billion, nearing half of last year's total [21] - The aerospace sector also saw increased activity, with companies like Shenjian Co. and Zengsheng Technology experiencing multiple limit-ups due to recent contract wins and upcoming launches [21] Company Updates - Maiwei Co. experienced a significant drop in stock price, attributed to market rumors regarding export restrictions on equipment and weak first-quarter performance expectations. However, the company has completed the first phase of equipment delivery for HJT production lines in the U.S. [16][18] - The optical fiber sector showed strong performance, with companies like Hengtong Optic-Electric and Changfei Optic-Fiber seeing stock price increases due to rising prices from operators and strong demand from data centers [19][23] - The agricultural sector also saw gains, driven by rising energy prices impacting fertilizer and logistics costs, which in turn raised expectations for agricultural product prices [23] Financial Performance - Zhaoyan New Drug reported a revenue of 1.658 billion yuan for 2025, a decrease of 17.87% year-on-year, but a net profit increase of 302.08% to 298 million yuan [27] - New Sharp Co. expects first-quarter revenue for 2026 to be between 1 billion and 1.15 billion yuan, a year-on-year increase of 89.28% to 117.68% [27] - Huazhi Precision anticipates a first-quarter net profit of 150 to 190 million yuan for 2026, reflecting a year-on-year growth of 413.28% to 550.15% [27] Industry Insights - Goldman Sachs has downgraded the target for the MSCI China Index and the CSI 300 Index by 5% and 4%, respectively, indicating a potential price return of 24% and 12% over the next 12 months [12] - The global economic backdrop is expected to lower the fair value of Chinese stocks by approximately 5%, with 2% attributed to profit deterioration and 3-4% due to a decline in the price-to-earnings ratio [11]

Market Overview - The A-share market opened lower but closed higher, with the Shenzhen Component Index rising over 1% [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.85 trillion, a decrease of 903 billion compared to the previous trading day [1][5] - More than 4,300 stocks in the market experienced gains, indicating a broad-based rally [1] Sector Performance - The lithium battery industry chain saw significant gains, with multiple stocks hitting the daily limit, including Rongjie Co., Ltd. with four consecutive limit-ups and Shida Shenghua with two consecutive limit-ups [1] - The pharmaceutical sector also performed well, with Keta Bio hitting the daily limit and several other stocks showing strong upward momentum [1] - The chemical sector was active, with stocks like Suli Co., Ltd. and Luban Chemical hitting the daily limit [1] Declines - In contrast, several stocks in the green energy sector experienced declines, with Liaoning Energy hitting the limit down and other companies like Jieneng Wind Power and Hunan Development also facing significant drops [2] Closing Statistics - At the close, the Shanghai Composite Index rose by 0.63%, the Shenzhen Component Index increased by 1.13%, and the ChiNext Index gained 0.71% [3][4]

3月27日午后，创新药概念持续走高，舒泰神涨超14%，昭衍新药、康弘药业、双鹭药业等多股涨停，神州细胞、首药控股、 百济神州、信立泰等均大幅上涨。 | 名称 | 涨跌幅▽ | 现价 | | --- | --- | --- | | 基石药业-B | 18.55% | 8.180 | | 石药集团 | 12.13% | 9.150 | | 华领医药-B | 10.93% | 3.450 | | 科济药业-B | 9.25% | 17.480 | | 映恩生物-B | 9.22% | 279.600 | | 先声药业 | 8.77% | 12.160 | | 亚盛医药-B | 7.95% | 46.160 | | 三生制药 | 7.46% | 23.340 | | 复宏汉霖 | 7.12% | 70.700 | | 恒瑞医药 | 7.10% | 65.600 | 编辑 ｜ 钉钉 | 名称 | 现价 | 涨跌幅 · | | --- | --- | --- | | 舒泰神 | 26.52 | 14.66% | | 迪哲医药-U | 57.12 | 10.70% | | 百利天恒 | 282.11 | 10.63% | ...

证券代码：002038 证券简称：双鹭药业 双鹭药业上市公司投资者关系活动记录表 编号：2026-001 | | √特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □电话会议 | | | □其他： （请文字说明其他活动内容） | | 参与单位名称 | 东方财富证券、汇银投资、工信部一所、千里马资本、信伟达资产、北 | | 及人员姓名 | 京产权交易所等机构投资者代表共计6人。 | | 时间 | 2026 年 3 月 26 日下午 14：00-16：00 | | 地点 | 双鹭药业会议室 | | 公司接待人员 | 公司董事兼董事会秘书梁淑洁女士 | | 姓名 | | | | 公司董事兼董事会秘书会秘书梁淑洁女士向参与调研人员简要介 | | | 绍了公司发展历史及概况，公司目前生产经营情况、重点研发产品的开 | | | 发进展、集采招标对公司的影响、新上市产品进入集采情况等，回答了 | | | 现场投资者的提问。具体交流情况如下： | | | 1、介绍了公司历史和发展概况 | | 投资 ...

Market Overview - The A-share market opened lower but rebounded, with all three major indices turning positive. The half-day trading volume in the Shanghai and Shenzhen markets was 1.14 trillion, a decrease of 84.3 billion compared to the previous trading day [1]. Stock Performance - Over 3,700 stocks in the market rose, indicating a broad-based rally [2]. Sector Highlights - The lithium mining sector saw significant gains, with Rongjie Co. achieving a four-day consecutive rise, while Jiangte Electric, Jinyuan Co., and Shengxin Lithium Energy hit the daily limit [3]. - The pharmaceutical sector also performed strongly, with Keta Bio reaching the daily limit, Meinuohua achieving five gains in six days, and Wanbangde recording three gains in four days. Lianhuan Pharmaceutical and Shuanglu Pharmaceutical also hit the daily limit [3]. - The chemical sector was active, with Sully Co., Lubai Chemical, and Jinzheng all reaching the daily limit [3]. Declines - In contrast, several stocks in the green energy sector experienced declines, with Liaoning Energy hitting the daily limit down, and both Jieneng Wind Power and Haili Wind Power seeing significant drops [4]. Closing Summary - By the end of the trading session, the Shanghai Composite Index rose by 0.26%, the Shenzhen Component Index increased by 0.93%, and the ChiNext Index was up by 0.83% [5].

Core Viewpoint - Beijing Shuanglu Pharmaceutical Co., Ltd. is facing severe financial difficulties, with a projected net profit loss of between -290 million to -200 million yuan for 2025, representing a maximum decline of 291.54% compared to the previous year [1][6]. Group 1: Investment Business - The company has expanded its investment portfolio over the past few years, focusing on early-stage equity investments in the pharmaceutical sector, participating in seven financing rounds since 2010, with investments ranging from tens of millions to over a hundred million yuan [7]. - In 2024, the company extended its investments into the securities market, but this led to significant fluctuations in performance due to market volatility [7]. - The company reported a fair value loss of 178 million yuan in 2024 due to stock price declines of its investments, while the first three quarters of 2025 saw a fair value gain of approximately 128 million yuan, which was later reversed in the fourth quarter, resulting in an overall loss for the investment business [2][7]. Group 2: Main Business Decline - Since 2021, the company's revenue has continuously declined from 1.215 billion yuan to 459 million yuan in the first three quarters of 2025 [8][11]. - The biopharmaceutical and biochemical segments saw revenue declines of 18.71% in the first half of 2025, while the chemical drug segment experienced a more significant drop of 27.54% due to the impact of centralized procurement policies [8]. - Sales of several core pharmaceutical products have significantly decreased, with the sales revenue of the core product in trauma repair, recombinant human basic fibroblast growth factor, dropping by 28.38% [9]. Group 3: Strategic and Financial Concerns - The dual challenges of investment losses and main business decline have led to a "dual-line loss" situation for the company, highlighting its inadequate response to industry policy adjustments and a lack of clear strategic direction [10]. - The company's early-stage equity investments are characterized by long cycles, high risks, and low liquidity, while its foray into securities investments has further amplified performance volatility [10]. - The ongoing centralized procurement policies have compressed profit margins for the company's pharmaceutical products, and specific measures to mitigate these risks have not been disclosed [10].

因购买私募产品导致一周亏损81%的圣元环保还未完全褪去热度，双鹭药业也因理财、炒股爆雷而成为外界关注的新焦点。 从去年三季报的业绩大幅增长到全年业绩的爆雷，这一突如其来的消息打击下，股价于2月2日应声跌停，并在两个交易日内下跌16.43%。 至于爆雷原因，公司公告表示，报告期内，公司非经常性损益合计减少净利润约2亿元，其中确认的理财投资损失与交易性金融资产等产生的公允价值变 动收益是主要影响因素。同时，公司表示，本报告期公司确认的损失包含投资理财损失，相关损失正在挽回中，董事长徐明波自愿承诺补足无法挽回的差 额，并将于一个月内先行上缴公司5000万元。 从表面上看，这是一起再正常不过因投资理财爆雷导致公司亏损的案例。然而，《每日经济新闻》记者梳理并统计相关数据发现，外界普遍认为的交易性 金融资产亏损可能并非双鹭药业2025年预亏的主要原因，相反，公司持有的几只股票甚至还可能为其带来不少利润；大概率爆雷的理财产品在近年的信披 内容有限：不仅没披露产品基本信息，更有50亿元的巨额信托理财产品去向成谜。 2026年1月30日晚，双鹭药业发布2025年度业绩预告，预计归属于上市公司股东的净利润为-29000万元至-2 ...

Core Viewpoint - The company, Shuanglu Pharmaceutical, is facing significant financial losses due to investment mismanagement, particularly in wealth management products, leading to a projected net loss of between 290 million to 200 million yuan for the fiscal year 2025, marking a year-on-year decline of 170.03% to 291.54% [1][2]. Group 1: Financial Performance and Losses - Shuanglu Pharmaceutical's net profit is expected to decline sharply, with a projected loss of 290 million to 200 million yuan, and a non-recurring loss of 70 million to 40 million yuan, reflecting a year-on-year decrease of 148.58% to 185.02% [1][2]. - The company's stock price dropped by 16.43% within two trading days following the announcement of the expected losses [2]. - The primary reason for the losses is attributed to a significant reduction in non-recurring gains, particularly from wealth management investments and fair value changes in financial assets, amounting to a net profit reduction of approximately 200 million yuan [2][4]. Group 2: Investment Management Issues - Despite the losses, the company holds several stocks that have appreciated in value, suggesting that the losses may not stem from these investments but rather from poorly disclosed wealth management products, including a mysterious 5 billion yuan trust product [2][10]. - The company has been criticized for its lack of transparency regarding its wealth management products, particularly high-risk trust products, with limited disclosure on their nature and performance [10][12]. - The company’s investment strategy has shifted towards higher-risk trust products since 2019, with a notable increase in wealth management investments reaching 6 billion yuan by mid-2025 [10][12]. Group 3: Corporate Governance and Actions - The chairman of Shuanglu Pharmaceutical, Xu Mingbo, has voluntarily committed to cover any irrecoverable losses from the wealth management investments, pledging to inject 50 million yuan into the company within a month [2][26]. - The rapid divestment by the company’s secretary following the release of the third-quarter report raises concerns about insider trading and the timing of information disclosure [30][33]. - The company has faced scrutiny over its governance practices, particularly regarding the management of investment risks and the decision-making process for wealth management investments [22][28].

Group 1 - The core issue revolves around the significant loss reported by Shuanglu Pharmaceutical, with a projected net profit loss of between -290 million to -200 million yuan for the year 2025, leading to a stock price drop of 16.43% within two trading days [1] - The company attributes the loss primarily to a reduction in non-recurring gains, which includes losses from financial investments and fair value changes of trading financial assets, amounting to approximately 200 million yuan [1] - The chairman of the company, Xu Mingbo, has voluntarily committed to cover any irrecoverable losses, pledging to contribute 50 million yuan to the company within a month [1] Group 2 - Despite the apparent financial turmoil, there are indications that the losses from trading financial assets may not be the main cause of the projected losses, as some held stocks could potentially yield profits [2] - There is a lack of transparency regarding the company's financial products, particularly a 5 billion yuan trust investment whose whereabouts remain unclear, raising concerns about disclosure practices [2] - The rapid divestment by the company's board secretary within seven trading days after the third-quarter report, which showed a year-on-year profit increase of over nine times, raises further questions about the company's financial management and governance [2]